Remember, your tox species has its own opinion about your TK profile. Go break some eggs.
Your Weekly Briefing:
👀 Insights
Anatomy of a TK Profile
Every nonclinical study spits out a TK profile. But what do AUC, Cmax, Tmax, and half-life actually mean — and how do regulators read them? In 7 minutes, I walk through each parameter, what it tells you about your drug, and how to interpret a real profile.
💭 Myths v. Realities
Myth: If your TK exposures match across species, the tox program is solid.
Reality: Matching exposures is the floor, not the finish line. Two species can hit the same AUC and Cmax and still tell completely different stories — different metabolites, different protein binding, different elimination pathways. TK is the entry ticket. The science is what's behind the curtain.
🔧 Tools
A cheat sheet for TK assessment.
🛠️ Why I Built My Course
Skip the years of trial and error.
Reading a TK profile, designing an IND-enabling study, knowing when to flag a finding — if you work in drug development, you'll need to know this. Most people pick it up the slow way: asking the wrong questions and getting the wrong answers, Googling terms during meetings, or throwing a study design at the wall and hoping it sticks.
The Complete Guide to Nonclinical Development is the shortcut. 60+ hours over 14 modules, real case studies and real decisions — taught entirely from the Sponsor side. Module 7 covers TK in depth, giving you the foundation to be the one your team turns to.
👇 The free preview shows you exactly what's inside: